Daily EPS Performer Reports

Stocks detected early by our EPS revision screener — and how they performed.

2026-10-16
VRATVCSGPBRBRALHC

VRA Jumps 13.8% as EPS Growth Estimate Revised to 150%

Vera Bradley (VRA) led our EPS revision screener with a 13.8% gain to $5.85 after its next-year EPS growth estimate was revised from 86.4% to 150%. Grupo Televisa (TV) rose 11.8% to $2.47, while CoStar Group (CSGP) and BellRing Brands (BRBR) each gained over 10% as upward estimate revisions drove broad-to-sector-specific momentum.

Read analysis →
2026-10-15
MRNAVRAWQEYRGENAGBK

MRNA Jumps 20.1% on EPS Revision and Goldman Upgrade; VRA, WQEY, RGEN Surge

Moderna (MRNA) leads today's EPS revision screen with a 20.1% gain to $236.50 since detection on October 8, driven by a 42.9% next-year EPS growth estimate and a Goldman Sachs price target hike ahead of key melanoma data. Vera Bradley (VRA) rose 16.5% after its next-year EPS growth estimate was revised from 86.4% to 150.0%, while WISeQey (WQEY) and Repligen (RGEN) gained 14.2% and 12.4% respectively on upward estimate revisions.

Read analysis →
2026-10-14
MRNANVAXAGBKWQEYVRA

MRNA Jumps 14.9%, NVAX Up 12.7% as Healthcare Stocks Ride EPS Revisions

Moderna (MRNA) surged 14.9% to $226.30 after its forward EPS growth estimate was revised to 42.9%, while Novavax (NVAX) rose 12.7% to $12.64 on a 20-percentage-point EPS revision for next year. Other notable gainers included AGBK (+10.4%), WQEY (+10.2%), and VRA (+9.5%), driven by upward earnings estimate revisions across sectors.

Read analysis →
2026-10-13
SEZLNVAXAGBKVRASNAP

SEZL Jumps 15% as EPS Growth Estimate Hits 27.3%

Sezzle (SEZL) led today's EPS-revision gainers with a 15.2% rally to $130.05 after our screener detected a 27.3% next-year EPS growth estimate on Oct 6, reinforced by its Nov 4 Q3 earnings date announcement. Novavax (NVAX) rose 14.3% on a +20.0pp upward revision to 97.3% growth, AGBK added 13.4% on a 44.5% estimate, while Vera Bradley (VRA) and Snap (SNAP) gained 12.4% and 11.7% respectively on upward EPS revisions.

Read analysis →
2026-10-12
SEZLNVAXRZLTSNAPPRCT

Sezzle Leads EPS Revision Screen with 15.6% Jump; NVAX, RZLT Follow

Sezzle (SEZL) jumped 15.6% to $130.48 after its next-year EPS growth estimate was revised to 27.3% on October 6, reinforced by TD Cowen's bullish note highlighting its 77% YTD gain and upcoming Q3 earnings. Novavax (NVAX) rose 12.8% to $12.66 following a 20-point upward revision to its next-year EPS growth estimate, while Rezolute (RZLT) gained 12.7% to $4.87 after the FDA recommended a pre-BLA meeting for Ersodetug despite a Phase 3 miss. Snap (SNAP) and PROCEPT BioRobotics (PRCT) also posted double-digit and near-double-digit gains, respectively, as estimate revisions and catalysts aligned.

Read analysis →
2026-10-10
SEZLNVAXRZLTAIDXFSM

Small-Cap EPS Revision Stocks Surge: SEZL +14%, NVAX +13.6% Lead

Sezzle (SEZL) led today's EPS revision screen with a 14.0% gain to $128.64 after analysts raised its next-year EPS growth estimate to 27.3% and the company scheduled Q3 results, while Novavax (NVAX) jumped 13.6% to $12.75 on a 20.0pp upward revision to its 2027 EPS growth outlook. Rezolute (RZLT) added 12.7% to $4.87 after the FDA recommended a pre-BLA meeting for Ersodetug, and Fortuna Mining (FSM) and 20/20 Biolabs (AIDX) gained 7.9% and 8.6% respectively as the market validated early estimate revisions across healthcare and materials.

Read analysis →
2026-10-09
PENGCLFSEZLRZLTJBS

PENG Jumps 24.3% on Raised FY27 Outlook; CLF, SEZL Also Surge

Penguin Solutions (PENG) gained 24.3% to $76.28 after analysts hiked price targets to as high as $100 on a Q4 beat and a raised fiscal 2027 EPS outlook of $4.45. Cleveland-Cliffs (CLF) jumped 14.7% to $12.98 after Wells Fargo upgraded the stock to Overweight with a $14 target. Sezzle (SEZL) rose 14.0% to $128.64, and Rezolute (RZLT) added 12.7% to $4.87 on an FDA pre-BLA meeting recommendation, while JBS gained 11.2% to $12.98.

Read analysis →
2026-10-08
PENGSOCAFRMJBSWLTH

PENG Soars 16.6% on AI Memory Beat; SOC, AFRM, JBS, WLTH Also Rally

Penguin Solutions (PENG) jumped 16.6% since October 2 after analysts raised forward EPS growth estimates to 29.2%, driven by a record fiscal Q4 with revenue up 68% to $567 million and 2027 guidance well above consensus. Sable Offshore (SOC) gained 10.0% on a 5.1pp EPS revision to 152.0%, while Affirm (AFRM) rose 9.5% ahead of Q3 earnings, and JBS and Wealthfront added 9.2% and 8.6% respectively on estimate upgrades.

Read analysis →
2026-10-07
PENGCOHRPSGOTUAVGO

PENG Soars 18.3% on AI Factory Blowout; COHR, AVGO Lead Tech Surge

Penguin Solutions (PENG) jumped 18.3% since its October 2 EPS revision detection, closing at $72.61 after a record fiscal Q4 that featured 68% revenue growth, non-GAAP EPS of $1.00 (beating 77-cent consensus), and a massive raised fiscal 2027 outlook. Coherent (COHR) gained 16.2% to $334.56 as AI infrastructure spending optimism lifted the entire semiconductor ecosystem, while Broadcom (AVGO) rose 9.6% to $376.51 on news it assembled $60 billion in debt financing to fund Anthropic AI chip infrastructure. The five-day rally across PENG, COHR, PS, GOTU, and AVGO reflects a market intensely rewarding companies that can prove AI-driven earnings acceleration.

Read analysis →
2026-10-06
NUPXSCOHRPSSTM

NU, PXS Lead Post-EPS Revision Rally: 26.8% and 19.6% Gains

Stocks flagged by our EPS revision screener have posted sharp gains, led by Nu Holdings (NU) up 26.8% to $15.66 and Pyxis Tankers (PXS) up 19.6% to $7.70 since detection on September 29. Coherent (COHR) added 17.6%, Pershing Square (PS) rose 13.2%, and STMicroelectronics (STM) climbed 10.0%, as upward revisions to next-year EPS growth estimates — ranging from 28.7% to 98.8% — attracted buyers despite a lack of company-specific earnings news for most names.

Read analysis →
2026-10-05
NUPXSLITECOHRCAMT

EPS Revisions Ignite Rally: NU Jumps 23%, PXS 23%, LITE 19%

Nu Holdings (NU) surged 22.9% to $15.18 and Pyxis Tankers (PXS) gained 22.8% to $7.91 after both were flagged by our EPS revision screener on September 29, with next-year EPS growth estimates of 28.7% and 39.0%, respectively. Lumentum (LITE) rose 18.5% to $1,091.67 following a similar screener detection on September 28 (57.6% next-year EPS growth) and a fresh earnings date announcement. Coherent (COHR) and Camtek (CAMT) also posted double-digit gains, bringing the average return of today's five top performers to 18.7%.

Read analysis →
2026-10-03
IMMPPXSLITECOHRCAMT

Immutep ADR Soars 1573% as EPS Growth Estimate Hits 25.5%

Immutep Limited ADR (IMMP) rocketed 1573.1% to $4.35 after its next-year EPS growth estimate was revised to 25.5%, leading a broad healthcare and tech rally. Lumentum (LITE) gained 17.8% to $1,085.42 and Coherent (COHR) rose 17.1% to $337.04, both driven by strong EPS growth projections of 57.6% and 49.9%, respectively. The moves suggest investors are aggressively pricing in future earnings acceleration across biotech and photonics.

Read analysis →
2026-10-02
IMMPIOVANNBRPXSLITE

Healthcare Stocks Lead: IMMP Surges 1573%, IOVA Jumps 31.7% After EPS Revisions

Immutep (IMMP) skyrocketed 1573.1% to $4.35 after its next-year EPS growth estimate was set at 25.5% following detection on September 27. Iovance Biotherapeutics (IOVA) gained 31.7% to $14.22 after raising FY2026 revenue guidance to $410-$420 million on September 29, reinforcing a 52.0% EPS growth estimate detected on September 24. Other top performers include NNBR (+25.3%), PXS (+20.0%), and LITE (+17.8%), all driven by upward EPS revisions.

Read analysis →
2026-10-01
IMMPIOVALITELUXEAMAT

IMMP Soars 1646% as IOVA, LITE Lead Post-EPS Revision Surge

Immutep (IMMP) skyrocketed 1646.2% to $4.54 after its next-year EPS growth estimate hit 25.5%, detected on September 27. Iovance Biotherapeutics (IOVA) jumped 31.8% to $14.23 following a $55 million revenue guidance raise, while Lumentum (LITE) gained 13.5% to $1045.78 as its EPS growth outlook reached 57.6%. These moves highlight the outsized impact of earnings estimate revisions, particularly in healthcare and technology.

Read analysis →
2026-09-30
IMMPIOVACDNLLUXERZLT

IMMP Soars 1688% as EPS Revisions Ignite Biotech Rally; IOVA Jumps 37%

Immutep (IMMP) rocketed 1,688.5% to $4.65 after its next-year EPS growth estimate was revised to 25.5% on September 27, leading a broad biotech rally. Iovance Biotherapeutics (IOVA) surged 37.2% to $14.82 following a raised FY2026 revenue outlook, while Cardinal Infrastructure, LuxExperience, and Rezolute added 5-9% on estimate revisions.

Read analysis →
2026-09-29
IOVACBRLLINDAMATNNBR

IOVA Jumps 33.8% on Raised 2026 Outlook; CBRL, AMAT Lead EPS Revision Rally

Iovance Biotherapeutics (IOVA) surged 33.8% to $14.45 after raising FY2026 revenue guidance to $410-$420 million, a $55 million midpoint increase that cleared consensus. Cracker Barrel (CBRL) added 17.0% to $52.48 following Q4 adjusted EBITDA of $62.1 million and upbeat FY2027 guidance. Applied Materials (AMAT) rose 10.3% to $512.01 as AI capex and services growth kept semiconductor spending in focus.

Read analysis →
2026-09-28
CBRLRZLTAMATLINDRVMD

Cracker Barrel Jumps 19.8% on EPS Estimate Surge: CBRL, RZLT, AMAT Lead

Cracker Barrel (CBRL) surged 19.8% to $53.73 after analysts revised its next-year EPS growth estimate from 2453.4% to 3811.4% on September 21, reinforced by strong Q4 FY2026 earnings that beat EBITDA expectations. Rezolute (RZLT) gained 6.1% to $4.18 on a 49.7% EPS growth estimate after its September 24 business update, while Applied Materials (AMAT) rose 4.8% to $486.76 on a 46.1% estimate amid AI-driven semiconductor demand. Lindblad Expeditions (LIND) and Revolution Medicines (RVMD) each added 4.8% and 4.7% respectively, as the EPS revision screener caught early momentum across consumer and healthcare sectors.

Read analysis →
2026-09-25
PTWSTCBRLMUON

EPS Revisions Fuel Tech Surge: P Jumps 21.2% as CBRL, TWST, MU, ON Rally

Five stocks detected by our EPS revision screener delivered strong gains, led by Everpure (P) surging 21.2% since September 17 after raising its fiscal 2028 outlook. Twist Bioscience (TWST) climbed 17.5% on EPS growth estimate of 37.1%, while Cracker Barrel (CBRL) jumped 15.5% following a massive EPS revision and better-than-expected Q4 results. Micron Technology (MU) and ON Semiconductor (ON) also posted double-digit gains, driven by positive earnings estimate revisions.

Read analysis →
2026-09-24
INTCTWSTABTCPMU

Intel, Everpure Lead EPS Revision Rally: INTC +26%, P +17%

Intel surged 26.1% since our EPS revision screener detected it on September 16, while Pure Storage (Everpure) jumped 17.2% after raising its fiscal 2028 revenue outlook to $7B-$7.3B. Twist Bioscience gained 18.3%, American Bitcoin rose 17.9%, and Micron climbed 16.6% as next-year EPS growth estimates topped 113% for the memory chipmaker.

Read analysis →
2026-09-23
FPSMSTRYSSABTCINTC

FPS Jumps 27% as EPS Revisions Fuel Industrials, Crypto Rally

Forgent Power Solutions (FPS) leads today's EPS revision winners with a 27.2% gain since its September 15 detection at $31.36, now at $39.88, as analysts forecast 54.5% next-year EPS growth. Strategy (MSTR) follows with a 25.1% rally to $162.20, bolstered by a 2.8pp EPS revision to 160.9% and a Bitcoin surge above $85,000. York Space Systems (YSS) (+23.7%), American Bitcoin (ABTC) (+21.7%), and Intel (INTC) (+21.3%) round out the top five, each benefiting from upward earnings estimate revisions that the market confirmed with strong price action.

Read analysis →
2026-09-22
MSTRHYFTCRDOYSSAMD

MSTR Jumps 29% on BTC Rally; HYFT, CRDO, YSS, AMD Also Surge on EPS Revisions

Strategy Inc (MSTR) led today's EPS-revision gainers with a 29.1% jump to $167.33 after Bitcoin's rally above $85,000 swung its 846,000 BTC holdings from a multibillion-dollar unrealized loss to an $8 billion profit, with analysts nudging the next-year EPS growth estimate from 158.1% to 160.9% at detection on September 15. HYFT, CRDO, YSS, and AMD each gained 26–29% since detection, as the screener caught quiet upward revisions to next-year growth estimates and the market confirmed them with broad price strength.

Read analysis →
2026-09-21
MSTRHYFTABTCYSSCRDO

MSTR Jumps 30%, HYFT 27.8%, ABTC 26.5%, YSS 25.6% as EPS Estimates Rise

Strategy Inc (MSTR) led our EPS revision screener's top performers with a 30.0% gain since September 15, driven by upward EPS estimate revisions and a broad cryptocurrency rally that pushed Bitcoin toward $85,000. MindWalk Holdings (HYFT) rose 27.8% after reporting 21% revenue growth and 59% gross margins in its Q1 FY2027 earnings. American Bitcoin Corp (ABTC) gained 26.5% on BTIG's initiation with a Buy rating and $15 price target, while York Space Systems (YSS) advanced 25.6% and Credo Technology (CRDO) climbed 24.8% in quiet trading.

Read analysis →
2026-09-18
CYPHPURRSUIGFPSFOSL

CYPH Jumps 63.6% as EPS Forecast Soars 2,560pp; FPS, PURR Lead Gainers

Cypherpunk Technologies (CYPH) surged 63.6% to $3.60 after its next-year EPS growth estimate was revised from 340.0% to 2,900.0% on September 10. Forgent Power Solutions (FPS) gained 25.8% to $39.44 following strong FY26 results and bullish analyst commentary, while Hyperliquid Strategies (PURR) and Sui Group Holdings (SUIG) rose 28.0% and 27.6% respectively on upward EPS revisions.

Read analysis →
2026-09-17
CYPHFOSLTWSTCRWDPURR

$CYPH Soars 39.5% as EPS Estimate Revision Drives Healthcare Rally

Cypherpunk Technologies (CYPH) surged 39.5% since September 10 after its next-year EPS growth estimate was revised from 340% to 2900%, dwarfing peer gains. Fossil Group (FOSL) jumped 25.4% on a similar upward revision, while Twist Bioscience (TWST), CrowdStrike (CRWD), and Hyperliquid Strategies (PURR) posted gains of 23.9%, 18.8%, and 16.5%, respectively, as the screener caught early earnings estimate revisions that the market validated with strong price action.

Read analysis →
2026-09-16
FOSLATECCRWDTWSTEVI

Fossil Surges 18.5% as EPS Revision Screener Flags 5 Stocks

Fossil Group (FOSL) leads today's EPS-revision winners with an 18.5% gain since detection, driven by a 664.7-percentage-point upgrade to its next-year EPS growth estimate. Alphatec (ATEC) added 16.9%, CrowdStrike (CRWD) rose 16.8% amid the AI-slowdown debate, Twist Bioscience (TWST) climbed 14.0%, and EVI Industries (EVI) advanced 11.5%. The screen's highest-conviction revision translated directly into the largest price move.

Read analysis →
2026-09-15
ATECFOSLNAVNTWSTEVI

ATEC Leads EPS Revision Screener Winners, Jumps 18.7% to $10.66

Alphatec Holdings (ATEC) jumped 18.7% to $10.66 after an 86.6% next-year EPS growth estimate surfaced, the strongest of five stocks flagged by our EPS revision screener since September 9. Fossil Group gained 12.2% following a massive 664.7 percentage-point upward revision to 776.2%, while Navan added 10.7% on raised guidance.

Read analysis →
2026-09-14
ATECCYPHCCGHUBSEVI

ATEC, CYPH, CCG, HUBS, EVI Surge 11-21% After EPS Estimate Revisions - Alphatec Holdings Leads

Alphatec Holdings (ATEC) jumped 20.9% to $10.86 after the EPS screener detected an 86.6% next-year growth estimate on September 9. Cypherpunk Technologies (CYPH) gained 17.3% following a massive 2560 percentage point EPS revision, while Cheche Group (CCG), HubSpot (HUBS), and EVI Industries (EVI) added 11-12% as upward earnings revisions drove buying across healthcare, communication services, technology, and industrials.

Read analysis →
2026-09-11
TELAAMBRMNTKBEGOLD

BE, TELA Lead EPS-Revision Rally: Bloom Energy and TELA Bio Surge 17-24%

Stocks flagged by our EPS-revision screener delivered strong gains from 2026-09-03 to 2026-09-11, led by TELA Bio (TELA) up 24.4% and Amber International (AMBR) up 18.7%. Bloom Energy (BE) jumped 17.1% after S&P 500 inclusion news reinforced its upward EPS estimate revision, while Gold.com (GOLD) added 16.2% on 99% revenue growth. The pattern shows early estimate revisions acting as a reliable precursor to price appreciation across healthcare, financials, industrials, and materials.

Read analysis →
2026-09-10
TELAMNTKPMVPAMBRMRVL

TELA Jumps 16.7%, MNTK 14.3% as EPS Estimates Get Revised Up

Small-cap and micro-cap names dominated today's EPS-revision leaderboard, with TELA Bio up 16.7% to $0.91 and Montauk Renewables up 14.3% to $2.55 since detection. Amber International rose 11.0% after its Q2 2026 print showed 38.8% sequential revenue growth and a swing to positive operating income. Marvell Technology added 9.9% to $226.96 as Wall Street's AI-infrastructure optimism reinforced its 60.1% next-year EPS growth estimate.

Read analysis →
2026-09-09
MNTKSKHYTELABEGOLD

MNTK leads EPS-revision surge: +39.8% as growth estimates climb to 35.3%

Montauk Renewables (MNTK) jumped 39.8% since September 1, when the screener flagged a 35.3% next-year EPS growth estimate, outpacing other top movers. SK Hynix (SKHY) gained 23.5% on AI memory demand, while Bloom Energy (BE) rose 14.3% on S&P 500 inclusion. The common thread: upward EPS revisions were confirmed by price action and sector catalysts.

Read analysis →